Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms

Full text
Scopim-Ribeiro, Renata [1, 2] ; Machado-Neto, Joao Agostinho [1, 2] ; Campos, Paula de Melo [2] ; Niemann, Fernanda Soares [2] ; Lorand-Metze, Irene [2] ; Costa, Fernando Ferreira [2] ; Olalla Saad, Sara Teresinha [2] ; Traina, Fabiola [1, 2]
Total Authors: 8
[1] Univ Sao Paulo, Sch Med, Dept Internal Med, BR-14049 Ribeirao Preto, SP - Brazil
[2] Univ Estadual Campinas, Hemoctr Unicamp, Inst Nacl Ciencia & Tecnol Sangue, Hematol & Hemotherapy Ctr, Rua Carlos Chagas 480, BR-13083878 Campinas, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: DIAGNOSTIC PATHOLOGY; v. 11, MAR 16 2016.
Web of Science Citations: 4

Background: New sequencing technologies have enabled the identification of mutations in Ten-eleven-translocation 2 (TET2), an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) in myeloid neoplasms. We have recently identified reduced TET2 mRNA expression in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), which is associated with a poor overall survival in MDS. We herein aimed to investigate TET2 mutations and their impact on TET2 expression in a cohort of patients with myeloid neoplasms, including MDS and AML patients. Findings: TET2 mutations were observed in 8 out of 19 patients (42 %) with myeloid neoplasms. The TET2 expression profile was similar between in wild type and in TET2 mutated patients. Conclusion: Our results suggest that TET2 expression is reduced in MDS/AML patients, independently of mutational status. (AU)

FAPESP's process: 11/51959-0 - Biology of neoplastic diseases of bone marrow
Grantee:Sara Teresinha Olalla Saad
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 12/09982-8 - Investigation of molecular alterations in myeloid neoplasms.
Grantee:Fabíola Traina
Support Opportunities: Regular Research Grants
FAPESP's process: 11/15905-3 - DNMT3A mutations, expression and function in myelodysplasic syndromes and acute myeloid leukemia.
Grantee:Renata Scopim Ribeiro
Support Opportunities: Scholarships in Brazil - Master